Content Conference Coverage Conferences ICAAC 2014
Coverage of IDWeek 2014
- Details
- Category: HIV Treatment
- Created on Friday, 17 October 2014 00:00
HIVandHepatitis.com coverage of IDWeek 2014, October 8-12, in Philadelphia.
Conference highlights include the HIV cascade of care, experimental antiretroviral therapies, interferon-free hepatitis C treatment, and news about other infectious diseases including Ebola virus and enterovirus D68.
Full listing of coverage by topic
10/17/14
Coverage of the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy
- Details
- Category: HIV Treatment
- Created on Monday, 08 September 2014 00:00
HIVandHepatitis.com coverage of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), September 5-9, in Washington, DC.
Conference highlights include experimental antiretroviral therapies for HIV, interferon-free treatment for hepatitis C, and news about other infectious diseases including tuberculosis, HPV, influenza, and Ebola virus.
Full listing of coverage by topic
9/8/14
ICAAC 2014: Cobicistat Long-term Efficacy Matches Ritonavir as PI Booster
- Details
- Category: Experimental HIV Drugs
- Created on Tuesday, 16 September 2014 00:00
Long-term rates of viral suppression and side effects were similar among people using cobicistat and those using ritonavir as a booster for atazanavir (Reyataz), according to 3-year data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC. Another study found that cobicistat was well-tolerated by people with mild-to-moderate kidney impairment.
ICAAC 2014: Stribild Works Well Regardless of Age, Sex, or Race/Ethnicity
- Details
- Category: Approved HIV Drugs
- Created on Tuesday, 23 September 2014 00:00
The elvitegravir-based Stribild single-tablet regimen demonstrated good long-term efficacy and tolerability -- including fewer neuropsychiatric side effects than Atripla -- with consistent results across demographic subgroups, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this month in Washington, DC. Other studies showed that Stribild is a good option for black patients either initiating or switching antiretroviral therapy (ART).
ICAAC 2014: NRTI BMS-986001 Safe and Effective, but Associated with Resistance
- Details
- Category: Experimental HIV Drugs
- Created on Friday, 12 September 2014 00:00
BMS-986001, an experimental HIV nucleoside reverse transcriptase inhibitor, was shown to be as effective as tenofovir with less bone loss, but more people who took it developed resistance, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC. Bristol-Myers Squibb has announced it will end its development of the drug.
More Articles...
- ICAAC 2014: PK Study Shows Feasibility of Long-acting Integrase Inhibitor Cabotegravir
- ICAAC 2014: New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones
- ICAAC 2014: Sangamo Provides Update on Gene Therapy to Protect T-cells From HIV
- ICAAC 2014: Tenofovir Vaginal Ring and Nanoparticle Gel Are Protective in Animal Studies
- ICAAC 2014: New Drug Isavuconazole Is Effective Against Opportunistic Fungal Infections
- ICAAC 2014: Telaprevir and Boceprevir Have Limited Efficacy in Real-world Use
- ICAAC 2014: AbbVie 3D Hepatitis C Regimen Is Well-Tolerated in Phase 3 Trials
- ICAAC 2014: AbbVie 3D Regimen Shows High Cure Rates for Genotype 1b HCV Patients
- ICAAC 2014: AbbVie 3D Combination Works Well for People with HIV/HCV Coinfection
- HCV Sexual Transmission: HIV Negative May Be at Risk, More Awareness and Testing Needed
- ICAAC 2014: Antibiotic Stewardship Programs Reduce Use and Improve Outcomes
- ICAAC 2014: IRIS and Risk of Early Death Among HIV+ People with Tuberculosis
- ICAAC 2014: Attempt to Shorten Standard Tuberculosis Treatment Fails in REMoxTB Trial
- ICAAC 2014: Anal HPV Infection and Dysplasia Common in HIV+ Women and Gay Men
- ICAAC 2014: Delafloxacin Shows Promise as a Single-dose Treatment for Gonorrhea
- ICAAC 2014: Single Dose of Flu Drug Peramavir Looks Safe and Effective
Web Design and Development by